Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/71800
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Goette, Andreas | - |
dc.contributor.author | Eckardt, Lars | - |
dc.contributor.author | Valgimigli, Marco | - |
dc.contributor.author | Lewalter, Thorsten | - |
dc.contributor.author | Laeis, Petra | - |
dc.contributor.author | Reimitz, Paul-Egbert | - |
dc.contributor.author | Smolnik, Rüdiger | - |
dc.contributor.author | Zierhut, Wolfgang | - |
dc.contributor.author | Tijssen, Jan G. | - |
dc.contributor.author | Vranckx, Pascal | - |
dc.date.accessioned | 2022-03-02T13:51:14Z | - |
dc.date.available | 2022-03-02T13:51:14Z | - |
dc.date.issued | 2021 | - |
dc.date.submitted | 2021 | - |
dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/73752 | - |
dc.identifier.uri | http://dx.doi.org/10.25673/71800 | - |
dc.description.abstract | Aims This subgroup analysis of the ENTRUST-AF PCI trial (ClinicalTrials.gov Identifier: NCT02866175; Date of registration: August 2016) evaluated type of AF, and CHA2DS2- VASc score parameters as predictors for clinical outcome. Methods Patients were randomly assigned after percutaneous coronary intervention (PCI) to either edoxaban (60 mg/30 mg once daily [OD]; n = 751) plus a P2Y12 inhibitor for 12 months or a vitamin K antagonist [VKA] (n = 755) plus a P2Y12 inhibitor and aspirin (100 mg OD, for 1–12 months). The primary outcome was a composite of major/clinically relevant non-major bleeding (CRNM) within 12 months. The composite efficacy endpoint consisted of cardiovascular death, stroke, systemic embolic events, myocardial infarction (MI), and definite stent thrombosis. Results Major/CRNM bleeding event rates were 20.7%/year and 25.6%/year with edoxaban and warfarin, respectively (HR [95% CI]: 0.83 [0.654–1.047]). The event rates of composite outcome were 7.26%/year and 6.86%/year, respectively (HR [95% CI]): 1.06 [0.711–1.587]), and of overall net clinical benefit were 12.48%/year and 12.80%/year, respectively (HR [(95% CI]: 0.99 [(0.730; 1.343]). Increasing CHA2DS2- VASc score was associated with increased rates of all outcomes. CHA2DS2- VASc score ≥ 5 was a marker for stent thrombosis. Paroxysmal AF was associated with a higher occurrence of MI (4.87% versus 2.01%, p = 0.0024). Conclusion After PCI in AF patients, increasing CHA2DS2- VASc score was associated with increased bleeding rates and CHA2DS2- VASc score (≥ 5) predicted the occurrence of stent thrombosis. Paroxysmal AF was associated with MI. These findings may have important clinical implications in AF patients. | eng |
dc.description.sponsorship | Projekt DEAL 2020 | - |
dc.language.iso | eng | - |
dc.relation.ispartof | http://link.springer.com/journal/392 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject | Atrial fibrillation | eng |
dc.subject | Coronary stenting | eng |
dc.subject | NOACs | eng |
dc.subject | CHA2DS2-VASc | eng |
dc.subject | Edoxaban | eng |
dc.subject.ddc | 610.72 | - |
dc.title | Clinical risk predictors in atrial fibrillation patients following successful coronary stenting : ENTRUST-AF PCI sub-analysis | eng |
dc.type | Article | - |
dc.identifier.urn | urn:nbn:de:gbv:ma9:1-1981185920-737520 | - |
local.versionType | publishedVersion | - |
local.bibliographicCitation.journaltitle | Clinical research in cardiology | - |
local.bibliographicCitation.volume | 110 | - |
local.bibliographicCitation.issue | 6 | - |
local.bibliographicCitation.pagestart | 831 | - |
local.bibliographicCitation.pageend | 840 | - |
local.bibliographicCitation.publishername | Springer | - |
local.bibliographicCitation.publisherplace | Berlin | - |
local.bibliographicCitation.doi | 10.1007/s00392-020-01760-4 | - |
local.openaccess | true | - |
dc.identifier.ppn | 1759423696 | - |
local.bibliographicCitation.year | 2021 | - |
cbs.sru.importDate | 2022-03-02T13:46:56Z | - |
local.bibliographicCitation | Enthalten in Clinical research in cardiology - Berlin : Springer, 2006 | - |
local.accessrights.dnb | free | - |
Appears in Collections: | Medizinische Fakultät (OA) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Goette et al._Clinical risk_2021.pdf | Zweitveröffentlichung | 1.28 MB | Adobe PDF | ![]() View/Open |